NRx Pharmaceuticals (NRXP) to Release Quarterly Earnings on Wednesday

NRx Pharmaceuticals (NASDAQ:NRXPGet Free Report) is projected to issue its quarterly earnings data after the market closes on Wednesday, March 26th. Analysts expect the company to announce earnings of ($0.30) per share for the quarter.

NRx Pharmaceuticals (NASDAQ:NRXPGet Free Report) last posted its quarterly earnings results on Friday, March 14th. The company reported ($0.30) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.20) by ($0.10). On average, analysts expect NRx Pharmaceuticals to post $-2 EPS for the current fiscal year and $0 EPS for the next fiscal year.

NRx Pharmaceuticals Stock Up 7.3 %

NASDAQ NRXP opened at $2.20 on Wednesday. The company has a 50-day simple moving average of $2.94 and a two-hundred day simple moving average of $2.02. NRx Pharmaceuticals has a 12-month low of $1.10 and a 12-month high of $6.01. The firm has a market cap of $37.22 million, a price-to-earnings ratio of -1.03 and a beta of 1.22.

Analyst Upgrades and Downgrades

A number of analysts have recently weighed in on the stock. Ascendiant Capital Markets increased their target price on shares of NRx Pharmaceuticals from $44.00 to $45.00 and gave the stock a “buy” rating in a report on Monday, December 2nd. HC Wainwright reiterated a “buy” rating and set a $19.00 target price on shares of NRx Pharmaceuticals in a report on Friday, March 14th. Finally, D. Boral Capital reiterated a “buy” rating and set a $31.00 target price on shares of NRx Pharmaceuticals in a report on Monday.

Read Our Latest Report on NRx Pharmaceuticals

NRx Pharmaceuticals Company Profile

(Get Free Report)

NRx Pharmaceuticals, Inc, a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned food and drug administration-designated breakthrough therapy for suicidal treatment-resistant bipolar depression; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of severe bipolar depression with acute suicidal ideation and behavior.

Read More

Earnings History for NRx Pharmaceuticals (NASDAQ:NRXP)

Receive News & Ratings for NRx Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NRx Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.